Novartis released positive data from the company’s FUTURE 5 clinical trial of Cosentyx (secukinumab) in psoriatic arthritis.
New Subcutaneous Formulation of Celltrion Healthcare’s Biosimilar CT-P13 Shows Positive Results for Treatment of Rheumatoid Arthritis
Annual European Congress of Rheumatology (EULAR 2019), Autoimmune Diseases, Biosimilars, Blockbusters, Clinical Data, Monoclonal Antibodies, R&D, Rheumatoid Arthritis (RA)Celltrion Healthcare presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with rheumatoid arthritis during the treatment period of one year.
